Clinical Cancer Research CR Helping Patients Frontiers in Basic Cancer Research
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Kim, K. J.
Right arrow Articles by Laterra, J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Kim, K. J.
Right arrow Articles by Laterra, J.
Clinical Cancer Research Vol. 12, 1292-1298, February 2006
© 2006 American Association for Cancer Research


Cancer Therapy: Preclinical

Systemic Anti–Hepatocyte Growth Factor Monoclonal Antibody Therapy Induces the Regression of Intracranial Glioma Xenografts

K. Jin Kim1, Lihong Wang1, Yi-Chi Su1, G. Yancey Gillespie2, Amandeep Salhotra3, Bachchu Lal3 and John Laterra3

Authors' Affiliations: 1 Galaxy Biotech, LLC, Mountain View, California; 2 Division of Neurosurgery, University of Alabama at Birmingham, Birmingham, Alabama; and 3 Department of Neurology, The Kennedy Krieger Research Institute and The Johns Hopkins University School of Medicine, Baltimore, Maryland

Requests for reprints: K. Jin Kim, Galaxy Biotech, LLC, 2462 Wyandotte Street, Mountain View, CA 94033. Phone: 650-964-4966, ext. 214; Fax: 650-694-7717; E-mail: kjinkim{at}msn.com.

Purpose: Hepatocyte growth factor (HGF) and its receptor Met are involved in the initiation, progression, and metastasis of numerous systemic and central nervous system tumors. Thus, an anti-HGF monoclonal antibody (mAb) capable of blocking the HGF-Met interaction could have broad applicability in cancer therapy.

Experimental Design: An anti-HGF mAb L2G7 that blocks binding of HGF to Met was generated by hybridoma technology, and its ability to inhibit the various biological activities of HGF was measured by in vitro assays. The ability of L2G7 to inhibit the growth of tumors was determined by establishing s.c. and intracranial xenografts of human U87 and U118 glioma cell lines in nude mice, and treatment with 100 µg of L2G7 or control given i.p. twice per week.

Results: MAb L2G7 strongly inhibited all biological activities of HGF measured in vitro, including cell proliferation, cell scattering, and endothelial tubule formation. Treatment with L2G7 completely inhibited the growth of established s.c. xenografts in nude mice. Moreover, systemic administration of L2G7 from day 5 induced the regression of intracranial U87 xenografts and dramatically prolonged the survival of tumor-bearing mice from a median of 39 to >90 days. L2G7 treatment of large intracranial tumors (average tumor size, 26.7 mm3) from day 18 induced substantial tumor regression (control group, 134.3 mm3; L2G7 treated group, 11.7 mm3) by day 29 and again prolonged animal survival.

Conclusions: These findings show that blocking the HGF-Met interaction with systemically given anti-HGF mAb can have profound antitumor effects even within the central nervous system, a site previously believed to be resistant to systemic antibody-based therapeutics.




This article has been cited by other articles:


Home page
JNMHome page
S. Nimmagadda, M. Pullambhatla, and M. G. Pomper
Immunoimaging of CXCR4 Expression in Brain Tumor Xenografts Using SPECT/CT
J. Nucl. Med., July 1, 2009; 50(7): 1124 - 1130.
[Abstract] [Full Text] [PDF]


Home page
Molecular Cancer TherapeuticsHome page
Y. Li, F. Guessous, C. DiPierro, Y. Zhang, T. Mudrick, L. Fuller, E. Johnson, L. Marcinkiewicz, M. Engelhardt, B. Kefas, et al.
Interactions between PTEN and the c-Met pathway in glioblastoma and implications for therapy
Mol. Cancer Ther., February 1, 2009; 8(2): 376 - 385.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
E. Vigna, G. Pacchiana, M. Mazzone, C. Chiriaco, L. Fontani, C. Basilico, S. Pennacchietti, and P. M. Comoglio
"Active" Cancer Immunotherapy by Anti-Met Antibody Gene Transfer
Cancer Res., November 15, 2008; 68(22): 9176 - 9183.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
M. J. Binning, T. Niazi, C. A. Pedone, B. Lal, C. G. Eberhart, K. J. Kim, J. Laterra, and D. W. Fults
Hepatocyte Growth Factor and Sonic Hedgehog Expression in Cerebellar Neural Progenitor Cells Costimulate Medulloblastoma Initiation and Growth
Cancer Res., October 1, 2008; 68(19): 7838 - 7845.
[Abstract] [Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
L. Toschi and P. A. Janne
Single-Agent and Combination Therapeutic Strategies to Inhibit Hepatocyte Growth Factor/MET Signaling in Cancer
Clin. Cancer Res., October 1, 2008; 14(19): 5941 - 5946.
[Abstract] [Full Text] [PDF]


Home page
The OncologistHome page
A. Idbaih, F. Ducray, M. Sierra Del Rio, K. Hoang-Xuan, and J.-Y. Delattre
Therapeutic Application of Noncytotoxic Molecular Targeted Therapy in Gliomas: Growth Factor Receptors and Angiogenesis Inhibitors
Oncologist, September 1, 2008; 13(9): 978 - 992.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
C. Basilico, A. Arnesano, M. Galluzzo, P. M. Comoglio, and P. Michieli
A High Affinity Hepatocyte Growth Factor-binding Site in the Immunoglobulin-like Region of Met
J. Biol. Chem., July 25, 2008; 283(30): 21267 - 21277.
[Abstract] [Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
Z. Tiran, A. Oren, C. Hermesh, G. Rotman, Z. Levine, H. Amitai, T. Handelsman, M. Beiman, A. Chen, D. Landesman-Milo, et al.
A Novel Recombinant Soluble Splice Variant of Met Is a Potent Antagonist of the Hepatocyte Growth Factor/Scatter Factor-Met Pathway
Clin. Cancer Res., July 15, 2008; 14(14): 4612 - 4621.
[Abstract] [Full Text] [PDF]


Home page
Molecular Cancer TherapeuticsHome page
L. P. Stabile, M. E. Rothstein, P. Keohavong, J. Jin, J. Yin, S. R. Land, S. Dacic, T. M. Luong, K. J. Kim, A. M. Dulak, et al.
Therapeutic targeting of human hepatocyte growth factor with a single neutralizing monoclonal antibody reduces lung tumorigenesis
Mol. Cancer Ther., July 1, 2008; 7(7): 1913 - 1922.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
S. Kim, U. J. Lee, M. N. Kim, E.-J. Lee, J. Y. Kim, M. Y. Lee, S. Choung, Y. J. Kim, and Y.-C. Choi
MicroRNA miR-199a* Regulates the MET Proto-oncogene and the Downstream Extracellular Signal-regulated Kinase 2 (ERK2)
J. Biol. Chem., June 27, 2008; 283(26): 18158 - 18166.
[Abstract] [Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
F. Ginty, S. Adak, A. Can, M. Gerdes, M. Larsen, H. Cline, R. Filkins, Z. Pang, Q. Li, and M. C. Montalto
The Relative Distribution of Membranous and Cytoplasmic Met Is a Prognostic Indicator in Stage I and II Colon Cancer
Clin. Cancer Res., June 15, 2008; 14(12): 3814 - 3822.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
H. Jin, R. Yang, Z. Zheng, M. Romero, J. Ross, H. Bou-Reslan, R. A.D. Carano, I. Kasman, E. Mai, J. Young, et al.
MetMAb, the One-Armed 5D5 Anti-c-Met Antibody, Inhibits Orthotopic Pancreatic Tumor Growth and Improves Survival
Cancer Res., June 1, 2008; 68(11): 4360 - 4368.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
S. F. Bellon, P. Kaplan-Lefko, Y. Yang, Y. Zhang, J. Moriguchi, K. Rex, C. W. Johnson, P. E. Rose, A. M. Long, A. B. O'Connor, et al.
c-Met Inhibitors with Novel Binding Mode Show Activity against Several Hereditary Papillary Renal Cell Carcinoma-related Mutations
J. Biol. Chem., February 1, 2008; 283(5): 2675 - 2683.
[Abstract] [Full Text] [PDF]


Home page
Mol Cancer ResHome page
T. E. Reznik, Y. Sang, Y. Ma, R. Abounader, E. M. Rosen, S. Xia, and J. Laterra
Transcription-Dependent Epidermal Growth Factor Receptor Activation by Hepatocyte Growth Factor
Mol. Cancer Res., January 1, 2008; 6(1): 139 - 150.
[Abstract] [Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
H. T. Jun, J. Sun, K. Rex, R. Radinsky, R. Kendall, A. Coxon, and T. L. Burgess
AMG 102, A Fully Human Anti-Hepatocyte Growth Factor/Scatter Factor Neutralizing Antibody, Enhances the Efficacy of Temozolomide or Docetaxel in U-87 MG Cells and Xenografts
Clin. Cancer Res., November 15, 2007; 13(22): 6735 - 6742.
[Abstract] [Full Text] [PDF]


Home page
Mol. Pharmacol.Home page
J. M. Siegfried, C. T. Gubish, M. E. Rothstein, P. E. Q. de Oliveira, and L. P. Stabile
Signaling Pathways Involved in Cyclooxygenase-2 Induction by Hepatocyte Growth Factor in Non Small-Cell Lung Cancer
Mol. Pharmacol., September 1, 2007; 72(3): 769 - 779.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Lung Cell. Mol. Physiol.Home page
M. M. Myerburg, J. D. Latoche, E. E. McKenna, L. P. Stabile, J. S. Siegfried, C. A. Feghali-Bostwick, and J. M. Pilewski
Hepatocyte growth factor and other fibroblast secretions modulate the phenotype of human bronchial epithelial cells
Am J Physiol Lung Cell Mol Physiol, June 1, 2007; 292(6): L1352 - L1360.
[Abstract] [Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
M. R.J. Carlson, W. B. Pope, S. Horvath, J. G. Braunstein, P. Nghiemphu, C.-L. Tso, I. Mellinghoff, A. Lai, L. M. Liau, P. S. Mischel, et al.
Relationship between Survival and Edema in Malignant Gliomas: Role of Vascular Endothelial Growth Factor and Neuronal Pentraxin 2
Clin. Cancer Res., May 1, 2007; 13(9): 2592 - 2598.
[Abstract] [Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
C. Bardella, D. Dettori, M. Olivero, N. Coltella, M. Mazzone, and M. F. Di Renzo
The Therapeutic Potential of Hepatocyte Growth Factor to Sensitize Ovarian Cancer Cells to Cisplatin and Paclitaxel In vivo
Clin. Cancer Res., April 1, 2007; 13(7): 2191 - 2198.
[Abstract] [Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
W. M. Linehan, P. A. Pinto, R. Srinivasan, M. Merino, P. Choyke, L. Choyke, J. Coleman, J. Toro, G. Glenn, C. Vocke, et al.
Identification of the Genes for Kidney Cancer: Opportunity for Disease-Specific Targeted Therapeutics
Clin. Cancer Res., January 15, 2007; 13(2): 671s - 679s.
[Abstract] [Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
T. Martens, N.-O. Schmidt, C. Eckerich, R. Fillbrandt, M. Merchant, R. Schwall, M. Westphal, and K. Lamszus
A Novel One-Armed Anti-c-Met Antibody Inhibits Glioblastoma Growth In vivo.
Clin. Cancer Res., October 15, 2006; 12(20): 6144 - 6152.
[Abstract] [Full Text] [PDF]


Home page
CarcinogenesisHome page
L. P. Stabile, J. S. Lyker, S. R. Land, S. Dacic, B. A. Zamboni, and J. M. Siegfried
Transgenic mice overexpressing hepatocyte growth factor in the airways show increased susceptibility to lung cancer
Carcinogenesis, August 1, 2006; 27(8): 1547 - 1555.
[Abstract] [Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
B. Peruzzi and D. P. Bottaro
Targeting the c-Met Signaling Pathway in Cancer.
Clin. Cancer Res., June 15, 2006; 12(12): 3657 - 3660.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
Copyright © 2006 by the American Association for Cancer Research.